Arthritis drug helps fight COVID-19

Doctor and senior man wearing medical masks

A medication called baricitinib (brand name Olumiant), which is commonly used to treat rheumatoid arthritis, reduces the risk of death by 13% in hospitalized COVID-19 patients who are also taking standard treatments such as dexamethasone, according to a draft research paper. The paper’s authors are among the investigators involved in the Recovery Clinical Trial, the world’s largest clinical trial of COVID-19 treatments, which is based in the U.K.

Previously, the Recovery Trial reported that dexamethasone was found to reduce deaths by one third, and that a medication called tocilizumab also reduced deaths when used in conjunction with dexamethasone.

The Recovery Trial has enrolled over 47,000 hospitalized COVID-19 patients. Trial results help to identify existing medications that can be used to treat COVID-19 infection, and provide options when new variants arise. They also help identify which drugs are not effective against COVID-19, such as aspirin and hydroxychloroquine.

See a report about the new findings at

Tell us what you think

This form does not collect your email address. If you would like us to respond, please send questions to
This field is for validation purposes and should be left unchanged.
We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today